25354-39-6

Upstream product

• 107-10-8 propylamine 
• 108-77-0 1,3,5-trichloro-2,4,6-triazine 

Downstream Products

• 1610533-91-9 N,N'-bis-(4-fluorobenzyl)-N-n-propyl-[1,3,5]triazine-2,4,6-triamine 
• 1522211-02-4 6-chloro-N-(4-fluorophenyl)-N'-n-propyl-[1,3,5]triazine-2,4-diamine 
• 1610533-65-7 O,N-dimethyl-N-[4-(n-propylamino)-6-(prop-2-ynylamino)-[1,3,5]triazin-2-yl]hydroxylamine DL-mandelate 
• 1610534-47-8 N-(3-chloro-2-methylbenzyl)-N'-n-propyl-N-prop-2-ynyl-[1,3,5]triazine-2,4,6-triamine 
• 1610534-46-7 N-(4-fluorophenyl)-N'-propyl-N''-prop-2-ynyl-[1,3,5]triazine-2,4,6-triamine hydrochloride 
• 1610534-45-6 N-(4-fluorophenyl)-N'-propyl-N''-prop-2-ynyl-[1,3,5]triazine-2,4,6-triamine 

Relevant academic research and scientific papers

Discovery and Optimization of Triazine Nitrile Inhibitors of Toxoplasma gondii Cathepsin L for the Potential Treatment of Chronic Toxoplasmosis in the CNS

With roughly 2 billion people infected, the neurotropic protozoan Toxoplasma gondii remains one of the most pervasive and infectious parasites. Toxoplasma infection is the second leading cause of death due to foodborne illness in the United States, causes severe disease in immunocompromised patients, and is correlated with several cognitive and neurological disorders. Currently, no therapies exist that are capable of eliminating the persistent infection in the central nervous system (CNS). In this study we report the identification of triazine nitrile inhibitors of Toxoplasma cathepsin L (TgCPL) from a high throughput screen and their subsequent optimization. Through rational design, we improved inhibitor potency to as low as 5 nM, identified pharmacophore features that can be exploited for isoform selectivity (up to 7-fold for TgCPL versus human isoform), and improved metabolic stability (t1/2 > 60 min in mouse liver microsomes) guided by a metabolite ID study. We demonstrated that this class of compounds is capable of crossing the blood-brain barrier in mice (1:1 brain/plasma at 2 h). Importantly, we also show for the first time that treatment of T. gondii bradyzoite cysts in vitro with triazine nitrile inhibitors reduces parasite viability with efficacy equivalent to a TgCPL genetic knockout.

Synthesis of new 5-aza-isosteres of guanine containing aryl and hetaryl substituents on the 1,2,4-triazole ring

The oxidative cyclization of 4-amino-substituted 6-arylidene(hetarylmethylidene)hydrazinyl-1,3,5-triazin-2-ones with lead(IV) tetraacetate proceeds via a Dimroth-type rearrangement to give 5-amino-substituted 2-aryl(hetaryl)-1,2,4-triazolo[1,5-a]-1,3,5-tr

NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME

The present invention includes compositions that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention.

Synthesis of 4-amino-6-chloro-1,3,5-triazin-2(1H)-ones

Conditions for selective substitution for one chlorine atom in 2-(R,R-amino)-4,6-dichloro-1,3,5-triazines with a hydroxide ion were elaborated. Spectral and calculation methods showed that the products formed are in the lactam form, i.e., have the structure of 4-chloro-6-(R,R- amino)-1,3,5-triazin-2(1H)-ones.

NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention, The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

Selectively functionalized glycerol/diacid dendrimers via click chemistry of azido fatty acids

Dendrimers consisting of glycerol and dicarboxylic acid units were synthesized using a convergent or "outside-in" strategy. The multimeric arms, or dendrons, are joined to a central core in the final step using the azide/alkyne click reaction. The combination of these approaches allows the preparation of dendrimers with variable and controlled degrees of substitution at their periphery. For example, a single protected amino acid has been situated at the periphery, with all other substituents being hydrophobic. In another example, all the peripheral substituents are protected amino acids. The identity of the dendrimers is unambiguous due to the purification and characterization of all the synthetic intermediates. Functional groups have also been selectively incorporated along the arms (dicarboxylic acids) and at the cores.

Identification and optimization of inhibitors of trypanosomal cysteine proteases: Cruzain, rhodesain, and TbCatB

Trypanosoma cruzi and Trypanosoma brucei are parasites that cause Chagas' disease and African sleeping sickness, respectively. Both parasites rely on essential cysteine proteases for survival: cruzain for T. cruzi and TbCatB/rhodesain for T. brucei. A rec

Bis(hydroxyamino)triazines: Versatile and high-affinity tridentate hydroxylamine ligands for selective iron(III) chelation

A new versatile family of chelating agents based on bis(hydroxyamino)-1,3, 5-triazines, BHTs, is described. The properties of different BHT ligands are determined by electrochemistry, spectroscopy and titrimetry revealing high redox stability, transparenc

N-(2,4-dihalo-S-triazin-6-yl)-ureas and process for their manufacture

A process for the manufacture of N-(2,4-dihalo-s-triazin-6-yl)-ureas of the formula SPC1 Wherein X represents halogen, R represents alkyl, aryl or hydrogen and Y represents hydrogen or the sulphonic acid group, which comprises reacting a dihalo-amino-s-triazine of the formula SPC2 Wherein X and R have the meanings assigned to them hereinbefore, with chloro-sulphonylisocyanate and hydrolysing the resulting reaction product. The compounds of the formula (1) are suitable as starting products for the manufacture of reactive dyes, fluorescent whiteners or agro - chemicals.